Workflow
Anhui Huaren Health Pharmaceutical (301408)
icon
Search documents
华人健康(301408) - 第五届监事会第八次会议决议公告
2025-05-21 13:15
证券代码:301408 证券简称:华人健康 公告编号:2025-041 安徽华人健康医药股份有限公司 第五届监事会第八次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整,没有虚 假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 安徽华人健康医药股份有限公司(以下简称"公司")第五届监事会第八次 会议已于 2025 年 5 月 16 日以书面、邮件送达形式发出通知,并于 2025 年 5 月 19 日在公司 6 楼 601 会议室以现场的方式举行,会议应到监事 3 名,实到监事 3 名。本次会议由监事会主席吴娟娟女士召集并主持。本次会议的召集和召开符 合相关法律法规及《公司章程》的规定,做出的决议合法有效。 经审议,监事会认为:董事会审议本次变更募集资金用途的程序符合《上市 公司监管指引第 2 号——上市公司募集资金管理和使用的监管要求》等中国证监 会和深圳证券交易所规范性文件及公司《公司章程》《募集资金管理制度》等的 相关规定,公司本次变更部分募集资金用途事项,符合公司当前实际和发展需要, 有利于提高募集资金使用效率和长远利益,符合公司及全体股东的利益,不存在 损害公司、投资者特别 ...
华人健康(301408) - 第五届董事会第九次会议决议公告
2025-05-21 13:15
证券代码:301408 证券简称:华人健康 公告编号:2025-040 安徽华人健康医药股份有限公司 第五届董事会第九次会议决议公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整,没有虚假记 载、误导性陈述或者重大遗漏。 一、董事会会议召开情况 安徽华人健康医药股份有限公司(以下简称"公司")第五届董事会第九次 会议已于 2025 年 5 月 16 日以书面、邮件送达形式发出通知,并于 2025 年 5 月 19 日在公司 6 楼 601 会议室以现场结合通讯的方式举行,本次会议应到董事 9 名,实到董事 9 名,其中董事鲁勖、殷俊、刘亮、程谋、李传润以通讯表决方式 出席。本次会议由公司董事长何家乐先生召集和主持,公司监事和高级管理人员 列席了会议。本次会议的召集和召开符合相关法律法规及《公司章程》的规定, 做出的决议合法有效。 二、董事会会议审议情况 本次会议审议并通过如下议案: 1、审议通过《关于收购福建、浙江三家医药连锁公司股权的议案》 经审议,董事会认为:本次交易符合公司"深耕安徽、聚焦华东、辐射周边" 的发展战略,通过整合目标公司的资源和优势,公司将进一步巩固在浙江和福建 市场的布局,形成 ...
华人健康:拟1.33亿元收购扬祖惠民46.01%股权
news flash· 2025-05-21 13:13
华人健康(301408)公告,公司计划以1.33亿元的价格购买扬祖惠民46.01%的股权、1.25亿元的价格购 买海华医药46.01%的股权,以及6825.98万元的价格购买桐庐怡生堂70.01%的股权。本次交易完成后, 目标公司将纳入公司合并报表范围。公司计划使用自有资金及变更部分募集资金用途进行支付,若变更 募集资金用途的审核未获批准,将全部使用自有资金支付。 ...
华人健康(301408) - 国浩律师(上海)事务所关于安徽华人健康医药股份有限公司2024年年度股东大会法律意见书
2025-05-16 12:34
上海市静安区山西北路 99 号苏河湾中心 MT25-28 楼 邮编:200085 25-28/F, Suhe Centre, 99 North Shanxi Road, Jing'an District, Shanghai 200085, China 电话/Tel: +86 21 5234 1668 传真/Fax: +86 21 5234 1670 网址/Website: http://www.grandall.com.cn 二零二五年五月 国浩律师(上海)事务所 关 于 安徽华人健康医药股份有限公司 2024 年年度股东大会 之 法律意见书 国浩律师(上海)事务所 关于安徽华人健康医药股份有限公司 2024 年年度股东大会之法律意见书 致:安徽华人健康医药股份有限公司 安徽华人健康医药股份有限公司(以下简称"公司")2024 年年度股东大会 于 2025 年 5 月 16 日召开。国浩律师(上海)事务所(以下简称"本所")经公 司聘请,委派律师出席现场会议,并根据《中华人民共和国公司法》(以下简称 "《公司法》")、《中华人民共和国证券法》(以下简称"《证券法》")等 法律、法规及中国证券监督管理委员会(以 ...
华人健康(301408) - 2024年年度股东大会决议公告
2025-05-16 12:34
证券代码:301408 证券简称:华人健康 公告编号:2025-034 1、本次股东大会未出现否决议案的情形。 2、本次股东大会未涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 (一)会议召开情况 1、会议召开时间 (1)现场会议召开时间:2025 年 5 月 16 日(星期五)下午 14:00。 安徽华人健康医药股份有限公司 2024 年年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚假 记载、误导性陈述或重大遗漏。 特别提示: (2)网络投票时间:通过深圳证券交易所互联网系统投票的时间为 2025 年 5 月 16 日 9:15-15:00;通过深圳证券交易所交易系统进行网络投票的时间为 2025 年 5 月 16 日上午 9:15-9:25,9:30-11:30,下午 13:00-15:00。 2、现场会议召开地点:安徽省合肥市包河区上海路 18 号华人健康大厦 6 楼 601 会议室。 3、会议召开方式:本次会议采取现场投票和网络投票相结合的方式召开。 4、会议召集人:董事会。 5、会议主持人:董事长何家乐。 章程》)的有关规定。 (二)会议出席情况 ...
华人健康(301408) - 关于归还用于临时补充流动资金的闲置募集资金的公告
2025-05-09 07:42
证券代码:301408 证券简称:华人健康 公告编号:2025-033 安徽华人健康医药股份有限公司 关于归还用于临时补充流动资金的闲置募集资金的 安徽华人健康医药股份有限公司(以下简称"公司")于 2024 年 6 月 24 日 召开了第五届董事会第三次会议和第五届监事会第三次会议,审议通过了《关于 使用闲置募集资金临时补充流动资金的议案》,同意在确保不影响公司募投项目 建设及募集资金正常使用计划的情况下,结合公司生产经营需求,使用不超过 15,000 万元的闲置募集资金临时补充流动资金,使用期限自董事会审议通过该 议案之日起不超过 12 个月,到期前将按时归还至募集资金专户。保荐机构华泰 联合证券有限责任公司出具了同意该事项的核查意见。具体内容详见公司于 2024 年 6 月 24 日披露的《关于使用闲置募集资金临时补充流动资金的公告》 (公告编号:2024-044)。 公司实际使用闲置募集资金 15,000 万元临时补充流动资金,在使用闲置募 集资金临时补充流动资金期间,公司严格遵守《上市公司监管指引第 2 号—上市 公司募集资金管理和使用的监管要求》《深圳证券交易所上市公司自律监管指引 第 2 号—创 ...
华人健康(301408) - 2025年5月8日投资者关系活动记录表
2025-05-08 10:34
Financial Performance - In 2024, the company's revenue reached CNY 4.532 billion, representing a growth of 19.34% compared to the previous year [2] - The net profit attributable to the parent company was CNY 138 million, marking a 20.09% increase year-on-year [2] R&D Investment Plans - Future R&D will focus on two main areas: 1. Digital empowerment and technology application, enhancing management efficiency and operational capabilities [3] 2. Drug research and capacity expansion, accelerating product development and leveraging advantages in fermentation technology [3] Store Expansion Strategy - In 2024, the company added 440 new stores through acquisitions, with plans to continue expanding its retail presence in the Anhui region and surrounding areas [3] Competitive Strategies - The company aims to strengthen its market position through: 1. Brand building and promotion to enhance market visibility [4] 2. Engaging in social responsibility initiatives to improve public perception [4] 3. Deepening member services to increase customer loyalty [4] 4. Implementing refined management practices to boost operational efficiency [5] 2025 Development Goals - The company plans to maintain a balanced development across its four core business segments: retail, agency, terminal procurement, and R&D [5] - It aims to enhance its brand market share and continue digital transformation efforts to support business growth [5] Response to Industry Policy Changes - The company is adapting to policy changes by: 1. Increasing R&D investment in high-potential products to enhance competitiveness [7] 2. Improving operational efficiency and cost management through digital transformation [7] 3. Strengthening brand and service value to maintain customer loyalty [7] 4. Actively participating in policy discussions to leverage market opportunities [7]
华人健康(301408) - 2025年4月29日投资者关系活动记录表
2025-04-30 00:46
Financial Performance - In 2024, the company achieved a record revenue of 4.532 billion CNY, a year-on-year increase of 19.34% [3] - The net profit attributable to the parent company was 138 million CNY, up 20.09% from the previous year [3] - In Q1 2025, revenue reached 1.267 billion CNY, reflecting a 14.71% increase year-on-year [3] - The net profit for Q1 2025 was 61.22 million CNY, marking a 28.15% growth compared to the same period last year [3] Strategic Initiatives - The significant growth is attributed to the "dual-driven, full-chain symbiosis" strategy, focusing on optimizing business structure and enhancing innovation [3] - The company is actively expanding in the elderly health sector, providing chronic disease training and services through pharmacies [4] - Development of the "Fuman Medical" series targeting common diseases in the elderly, alongside the "Guojin" series of traditional Chinese medicine products [4] Brand Development - The company has established a comprehensive self-owned brand system with over 700 agency products covering various medical categories [5] - The "Shenhua Weikang" product line has seen substantial sales growth, indicating strong market potential [5] - The company is expanding its online retail presence through platforms like Douyin, JD, Tmall, and Pinduoduo [5] Market Expansion - The company plans to deepen its market presence in Zhejiang and Fujian, focusing on both existing advantages and new growth opportunities [6] - The "1234 strategy" aims to enhance collaboration across four major business platforms, creating a cohesive pharmaceutical health ecosystem [7] Future Outlook - The company will continue to expand its store network through new openings, acquisitions, and franchises, solidifying its leading position in Anhui [8] - Emphasis on balanced development across core business segments while enhancing brand influence and market share [8] - Ongoing commitment to digital transformation and operational efficiency to support high-quality growth [8]
华人健康(301408) - 关于举办2024年度暨2025年第一季度业绩说明会的公告
2025-04-28 08:32
4 、 会 议 问 题 征 集 : 投 资 者 可 于 2025 年 5 月 8 日前访问网址 https://eseb.cn/1nOs3jqe5m8 或使用微信扫描下方小程序码进行会前提问,公 司将通过本次业绩说明会,在信息披露允许范围内就投资者普遍关注的问题进行 回答。 安徽华人健康医药股份有限公司(以下简称"公司")已分别于 2025 年 4 月 25 日、29 日在巨潮资讯网上披露了《2024 年年度报告》及《2024 年年度报 告摘要》、《2025 年第一季度报告》。为便于广大投资者更加全面深入地了解公 司经营业绩、发展战略等情况,公司定于 2025 年 5 月 8 日(星期四)15:00-16:00 1、会议召开时间:2025 年 5 月 8 日(星期四)15:00-16:00 2、会议召开方式:网络互动方式 3、会议召开地点:价值在线(www.ir-online.cn) 证券代码:301408 证券简称:华人健康 公告编号:2025-032 安徽华人健康医药股份有限公司 关于举办2024年度暨2025年第一季度业绩 说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚 ...
华人健康(301408) - 2025 Q1 - 季度财报
2025-04-28 08:30
Financial Performance - The company's revenue for Q1 2025 reached ¥1,266,847,107, representing a 14.71% increase compared to ¥1,104,366,687 in the same period last year[5] - Net profit attributable to shareholders was ¥61,222,277, up 28.15% from ¥47,772,301 in the previous year[5] - Basic earnings per share rose to ¥0.1531, reflecting a 28.22% increase from ¥0.1194 in the previous year[5] - The net profit for the current period is CNY 65,083,948.27, an increase of 24% compared to CNY 52,500,362.09 in the previous period[22] - The operating profit for the current period is CNY 84,384,004.88, up from CNY 69,401,473.12, reflecting a growth of approximately 21.6%[22] - The total comprehensive income attributable to the parent company is CNY 61,222,277.52, compared to CNY 47,772,301.04 in the previous period, marking a 28% increase[23] Cash Flow and Assets - The net cash flow from operating activities increased by 130.62% to ¥363,317,692 from ¥157,539,855 year-on-year[5] - The company's cash and cash equivalents decreased to ¥788,141,526.89 from ¥999,693,750.44, a decline of 21.11%[18] - The total cash and cash equivalents at the end of the period is CNY 320,092,515.84, down from CNY 572,496,711.00 at the end of the previous period[24] - The company reported a foreign exchange impact of CNY -7,532.83 on cash and cash equivalents[24] Operating Costs and Expenses - Operating costs increased by 13.47% to ¥841,486,683.18, driven by sales growth[10] - Total operating costs amounted to ¥1,175,205,083.11, up 13.76% from ¥1,032,719,031.44 in the prior period[21] - The company reported a significant increase in research and development expenses to ¥6,522,397.24, up from ¥6,196,651.12, indicating a focus on innovation[21] Shareholder Information - The total number of common shareholders at the end of the reporting period is 17,951[12] - The largest shareholder, He Jiale, holds 50.12% of shares, totaling 200,493,326 shares, with 51,000,000 shares pledged[12] - The second-largest shareholder, He Jialun, holds 6.89% of shares, totaling 27,572,335 shares[12] - The total number of shares held by the top 10 shareholders accounts for a significant portion of the company's equity, with the top four shareholders holding over 66% combined[12] - The company has no preferred shareholders as per the report[14] Investments and Future Plans - The company reported a significant increase in trading financial assets, which rose by 2656.27% to ¥275,626,500 due to increased investments in financial products[10] - The company plans to continue expanding its retail store network to support revenue growth in the future[10] - The company plans to expand its market presence and invest in new technologies, although specific strategies were not detailed in the call[21] Liabilities and Assets Overview - Total assets at the end of the reporting period were ¥4,951,051,382.59, a 2.55% increase from ¥4,828,108,351.67 at the end of the previous year[5] - Total liabilities rose to ¥2,825,502,684.35, an increase of 2.09% from ¥2,767,673,601.70[20] Miscellaneous - The company received government subsidies totaling ¥1,205,938.16, which positively impacted its financial performance[6] - The company recorded a 43.62% increase in asset disposal gains, amounting to ¥915,251.57, primarily from the disposal of non-current assets[10] - There are no changes in the restricted shares for major shareholders during the reporting period[15] - The company did not conduct an audit for the first quarter report[25]